Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient ![](images/questionmark.png)
●  The left chart: Distribution of similarity level between NPC190949 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 24169 |
0.1-0.2 | 4676 |
0.2-0.3 | 1559 |
0.3-0.4 | 375 |
0.4-0.5 | 75 |
0.5-0.6 | 26 |
0.6-0.7 | 7 |
0.7-0.8 | 1 |
0.8-0.85 | 0 |
0.85-0.9 | 1 |
0.9-0.95 | 0 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC190949 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 1883 |
0.1-0.2 | 4352 |
0.2-0.3 | 1979 |
0.3-0.4 | 736 |
0.4-0.5 | 154 |
0.5-0.6 | 29 |
0.6-0.7 | 22 |
0.7-0.8 | 4 |
0.8-0.85 | 0 |
0.85-0.9 | 2 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8889 |
High Similarity |
NPD8186 |
Phase 1 |
0.8889 |
High Similarity |
NPD8185 |
Discontinued |
0.766 |
Intermediate Similarity |
NPD9210 |
Phase 2 |
0.732 |
Intermediate Similarity |
NPD9190 |
Approved |
0.732 |
Intermediate Similarity |
NPD9189 |
Discontinued |
0.717 |
Intermediate Similarity |
NPD9412 |
Discontinued |
0.6923 |
Remote Similarity |
NPD8584 |
Approved |
0.6909 |
Remote Similarity |
NPD163 |
Approved |
0.6893 |
Remote Similarity |
NPD9197 |
Discontinued |
0.6863 |
Remote Similarity |
NPD9134 |
Approved |
0.6863 |
Remote Similarity |
NPD9135 |
Approved |
0.6863 |
Remote Similarity |
NPD9255 |
Phase 2 |
0.6827 |
Remote Similarity |
NPD8861 |
Approved |
0.6827 |
Remote Similarity |
NPD8859 |
Approved |
0.6827 |
Remote Similarity |
NPD8862 |
Approved |
0.6762 |
Remote Similarity |
NPD9502 |
Clinical (unspecified phase) |
0.6698 |
Remote Similarity |
NPD9345 |
Clinical (unspecified phase) |
0.6698 |
Remote Similarity |
NPD9415 |
Clinical (unspecified phase) |
0.6698 |
Remote Similarity |
NPD9371 |
Clinical (unspecified phase) |
0.6698 |
Remote Similarity |
NPD9196 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD9629 |
Approved |
0.6604 |
Remote Similarity |
NPD9195 |
Approved |
0.6566 |
Remote Similarity |
NPD8787 |
Clinical (unspecified phase) |
0.6542 |
Remote Similarity |
NPD9414 |
Approved |
0.6514 |
Remote Similarity |
NPD613 |
Phase 2 |
0.65 |
Remote Similarity |
NPD8786 |
Approved |
0.6195 |
Remote Similarity |
NPD9182 |
Approved |
0.6174 |
Remote Similarity |
NPD9132 |
Discontinued |
0.5935 |
Remote Similarity |
NPD300 |
Approved |
0.592 |
Remote Similarity |
NPD9081 |
Clinical (unspecified phase) |
0.5873 |
Remote Similarity |
NPD9650 |
Phase 3 |
0.5772 |
Remote Similarity |
NPD1388 |
Phase 1 |
0.5772 |
Remote Similarity |
NPD1389 |
Clinical (unspecified phase) |
0.5772 |
Remote Similarity |
NPD1390 |
Phase 1 |
0.5766 |
Remote Similarity |
NPD341 |
Approved |
0.5766 |
Remote Similarity |
NPD340 |
Approved |
0.5614 |
Remote Similarity |
NPD1816 |
Clinical (unspecified phase) |
0.5607
|
Remote Similarity |
NPD8838 |
Approved |